Financial Performance - The company's operating revenue for the reporting period was CNY 154,007,522.39, a decrease of 28.86% compared to the same period last year[3]. - The total profit for the reporting period was CNY 28,558,598.64, down 45.97% year-on-year[3]. - The net profit attributable to shareholders was CNY 23,261,866.15, reflecting a decline of 48.95% compared to the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 11,396,652.46, a decrease of 69.65% year-on-year[3]. - Basic earnings per share were CNY 0.33, down 51.47% from the same period last year[3]. Assets and Equity - Total assets at the end of the reporting period were CNY 537,925,286.05, an increase of 3.06% from the beginning of the period[4]. - Shareholders' equity attributable to the company was CNY 474,712,203.17, up 0.88% from the beginning of the period[4]. Market Conditions - The decline in performance was primarily due to decreased market demand for raw materials and increased competition in the glucose acid salt series[6]. - The market demand for vitamin and cold medicine products weakened in 2024, leading to a decline in sales and prices, which affected the gross margin of formulation products[6]. Cautionary Note - The company warns that the financial data is preliminary and has not been audited, urging investors to be cautious[7].
新赣江(873167) - 2024 Q4 - 年度业绩